Understanding how GPR34 affects immune cell movement and function in cancer
Dissecting the role of GPR34 in cDC1 migration and function
This study is looking at how a special receptor called GPR34 helps certain immune cells, which are key in fighting cancer and infections, move to where they are needed most, like inflamed areas and tumors, to see if this can lead to better cancer treatments.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10912531 on NIH RePORTER |
What this research studies
This research investigates the role of a specific receptor, GPR34, in the movement and function of immune cells called type 1 conventional dendritic cells (cDC1s), which are important for fighting cancer and infections. The study will explore how GPR34 influences the migration of these cells to areas of inflammation and tumors, potentially affecting their ability to present antigens to CD8+ T cells. By examining these processes in detail, the research aims to uncover new insights into how the immune system can be harnessed to improve cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that may involve immune system interactions, particularly those with colon or ovarian cancer.
Not a fit: Patients with non-cancerous conditions or those not involving immune system modulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing immune responses against cancer.
How similar studies have performed: Other research has shown promising results in understanding immune cell migration and function, making this approach both relevant and potentially impactful.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Tam, Hanson Peter — University of California, San Francisco
- Study coordinator: Tam, Hanson Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.